Document is current
Any future updates will be listed below
-
Authors
Nshimiyimana, Ladislas
Rujeni, Nadine
Mbituyumuremyi, Aimable
Ower, Alison
Mbonigaba, Jean Bosco
Palacio, Karen
Musarurwa, Cuthbert
Uwizeyimana, Jeanne
Hitiyaremye, Nathan
Tuyishime, Albert
Huston, Tonya
Nyandwi, Elias
Ruberanziza, Eugene
-
Funding
Funding for this research was provided by:
The End Fund
- License Information
-
More Information
Article History
Received: 12 October 2025
Accepted: 4 February 2026
First Online: 16 February 2026
Declarations
:
: The authors declare no competing interests.
: The study received approval from the Rwanda National Research Ethics Committee (Approval No. RNEC631/2024). Written informed consent was obtained from all adult participants, and parental or guardian consent was sought for minors, with assent obtained from children aged 7–15 years. All data were anonymized, and confidentiality was maintained through password-protected databases. Participants diagnosed with STH or SCH were treated in line with national guidelines using albendazole or praziquantel, respectively. All procedures were performed in accordance with the Declaration of Helsinki and the national regulations on human research.
